Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (26679)	11/25/1998 2:56:00 PM
From: Russian Bear	Respond to of 32384

>>Should I remind you of Redux, Phen-Phen, and WLA diabetic drug, Rezulin(sp) as to the issue of safety and the end result of having a drug approved.(:>)<< TD, Why would lay committee members make it any less likely that what ultimately prove to be undesirable compounds successfully make it through the approval process? I agree with George. As far as I can tell, all they add to the mix is an increased level of unpredictability (i.e., a higher variance.) The FDA makes very important decisions -- life and death, in many cases -- and committee members should, ideally, be selected based on their experience and good judgement, not on any misguided quota system. On an entirely unrelated topic: Happy Thanksgiving to you and to all on the thread! Best regards, RB